Luminera's HArmonyCa is a dermal filler intended for facial soft tissue augmentation that is comprised of a combination of cross-linked hyaluronic acid (HA) with embedded calcium hydroxyapatite (CaHA) microspheres.

Allergan Aesthetics, an AbbVie company, has acquired Luminera's full dermal filler portfolio and R&D pipeline.

Luminera is a privately held aesthetics company based in Israel with a portfolio and pipeline of dermal filler products.  

"The addition of the Luminera assets adds innovative technology, complementing our leading JUV DERM filler franchise.  We welcome the Luminera team as we continue to build our global aesthetics company and a world-class product offering for healthcare professionals and patients around the world," says Carrie Strom, SVP, AbbVie, and President, Global Allergan Aesthetics, in a news release.

Luminera Chairman Dadi Segal, PhD, adds, "We believe bringing together key, innovative Luminera assets with the support of Allergan Aesthetics will provide an even brighter future for our people, products and a more expanded offering for our customers.  This is a tremendous opportunity to further build, develop and collaborate with a leading global aesthetics company." 

Luminera's HArmonyCa is a dermal filler intended for facial soft tissue augmentation that is comprised of a combination of cross-linked hyaluronic acid (HA) with embedded calcium hydroxyapatite (CaHA) microspheres.  The combination of HA and CaHA in a single product is highly differentiated in the dermal filler category. 

HArmonyCa is currently commercially available in Israel and Brazil. Allergan Aesthetics will continue to develop this product for its International and US markets.  

The Luminera dermal filler portfolio also includes a line of HA dermal fillers, as well CaHA based fillers commercialised across several markets.  Brands include Crystalys, Hydryalix and Hydryal.